ArticleBMC psychiatry2025
Effects of oxidative stress and GDNF on patients with bipolar disorder: a prospective study.
Article in BMC psychiatry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Limitations of registry proxies: Why the search for a better cardiovascular disease risk model in bipolar disorder must continue.Molecular psychiatry · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundBipolar disorder (BD) is a common mental disorder characterized by significant cognitive dysfunction, the mechanisms of which remain unclear. Oxidative stress and glial cell line-derived neurotrophic factor (GDNF) influence the pathophysiology of BD. Their specific roles, particularly concerning cognitive function during manic episodes, are unclear. The serum levels of superoxide dismutase (SOD) and malondialdehyde (MDA), and GDNF were biochemically assayed in patients with bipolar mania before and after treatment to explore their associations with cognitive function.
methodsA total of 75 patients in acute manic episodes of BD and 70 healthy controls were initially enrolled. During the 4-week intervention period with atypical antipsychotics and mood stabilizers, 5 patients discontinued follow-up, resulting in 70 completers included in the final analysis. The severity of manic symptoms were assessed using the Young Mania Rating Scale (YMRS). Cognitive function was assessed by the Digit Cancellation, Stroop Color and Word, and Trail Making Tests. Serum levels of SOD, MDA, and GDNF were measured using biochemical assays.
resultsBD patients demonstrated higher serum SOD and MDA levels and lower GDNF levels compared to controls, following improvements after treatment. Pre-treatment YMRS scores and cognitive function assessments positively correlated with SOD and MDA levels, and negatively correlated with GDNF levels. Treatment significantly improved manic symptoms and cognitive function, although GDNF levels remained lower than in controls.
conclusionsThe demonstrated associations with symptoms and cognitive functions during the manic phase substantially advance the understanding of the role of oxidative stress and GDNF in BD. Possible biomarkers for BD diagnosis and prognosis assessment are revealed. Further investigations into the complex pathophysiological mechanisms of BD are needed. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.